Skip to content
Screener

CONMED CNMD Q2 2026 earnings

Reported July 29, 2026 · After market close

Revenue$343.5MBeat by $5.9M
EPS$1.38Beat by $0.27
Revenue estimate$337.6M
EPS estimate$1.11
“Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace. In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team.”
Patrick J. Beyer

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$336.3M
EPS estimate$1.00

Financials

Q2 2026

Income statement

See full
Revenue$343.5M+0.3%
Gross profit$197.5M+4.9%
Operating income$36.4M-4.6%
Net income$23.1M+7.7%
EPS (diluted)$0.77+11.6%

Balance sheet

See full
Cash & equivalents$37.3M+10.0%
Total debt$1.0B+14.5%
Total equity$1.0B+3.8%
Total assets$2.3B-1.2%

Cash flow

See full
Operating cash flow$37.1M+27.3%
CapEx$2.9M-48.8%
Free cash flow$34.2M+46.0%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.41B-9.8%
Enterprise value$2.38B-1.2%
P/E24.9×+10.8×
P/S1×-0.2×

Profitability

See full
Gross margin55.8%-0.3pp
Operating margin8%-5.0pp
Net margin4.1%-4.2pp
FCF margin9.8%-1.4pp

Returns & leverage

See full
Return on equity5.5%-6.2pp
Debt / equity1×+0.1×
Current ratio1.5×-0.7×

Segments

By geography

See full
Europe, Middle East & Africa$76.1M+12.3%
Asia Pacific$57.2M+9.7%
Americas (excluding the United States)$34.8M+9.2%

By product

See full
General Surgery$191.2M-5.2%
Orthopedic Surgery$152.3M+8.2%

FAQ

When did CONMED report Q2 2026 earnings?
CONMED (CNMD) reported Q2 2026 earnings on July 29, 2026 after market close.
What were CONMED's Q2 2026 revenue and EPS?
CONMED reported revenue of $343.5M and eps of $1.38 for Q2 2026.
Did CONMED beat estimates in Q2 2026?
Revenue beat the consensus estimate of $337.6M by $5.9M. EPS beat the consensus estimate of $1.11 by $0.27.
How did CONMED's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.3% from $342.3M a year earlier and eps grew 20.0% from $1.15.
Where can I find CONMED's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000816956-26-000101) and the 10-Q periodic report (0000816956-26-000102) directly on SEC EDGAR. The filing index links above go to sec.gov.